
aTyr Pharma Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
aTyr Pharma, Inc. is a biotherapeutics company engaged in the discovery and development of medicines based on novel immunological pathways. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors.
Key slides for aTyr Pharma Inc


Investor Presentation
aTyr Pharma Inc


Investor Presentation
aTyr Pharma Inc
Latest articles

Marvel-ous Reporting: Marvel’s Comic Inspired Reports
Shareholder reports are often considered tedious and dry. However, in the late 1980s and early 1990s, Marvel Comics revolutionized this perception by transforming its financial reports into captivating comic books.
8 Dec 2023

The Payments Value Chain: A Complex Ecosystem
The payments industry is a complex and dynamic field involving multiple key players. These include customers, merchants, issuers, acquirers, card networks, and various other entities together forming the payments value chain.
8 Dec 2023

NIBE: Creating Millionaires and a Greener Future
NIBE, just like IKEA, was founded in a rural part of Sweden called Småland. The company offers a wide range of pumps, wood stoves, and solar panels.
6 Dec 2023
Ticker symbol
LIFE
Country
🇺🇸 United States